Status:

COMPLETED

Acceptance of a Partially Hydrolyzed Formula

Lead Sponsor:

Mead Johnson Nutrition

Conditions:

Fussy Infant (Baby)

Eligibility:

All Genders

15-75 years

Phase:

NA

Brief Summary

A multi-center, double-blind, controlled, parallel-designed, prospective trial intended to evaluate the nutritive effects of a partially hydrolyzed cow's milk protein infant formula on infant fussines...

Detailed Description

A multi-center, double-blind, controlled, parallel-designed, prospective trial intended to evaluate the nutritive effects of a partially hydrolyzed cow's milk protein (PHP) infant formula on infant fu...

Eligibility Criteria

Inclusion

  • Primary caregiver has reliable access to the internet and a reliable device (such as a computer, tablet, or smartphone) to access mobile apps and be able to view and complete study questionnaires
  • Singleton birth
  • 15 to 75 days of age at Visit 1, inclusive (day of birth is considered Day 0)
  • Gestational age of ≥37 to 42 weeks (36 weeks and six days is considered 36 weeks' gestational age)
  • Birth weight of 2500 g (5 lbs 8 oz) or more
  • Exclusively receiving an intact protein infant formula (cow's milk-based or plant-based) for 7 days prior to Visit 1
  • Answer to question: "On average, how fussy has your baby been over the past 3 days" is moderately fussy, very fussy, or extremely fussy at Visit 1
  • Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period
  • Parent(s) or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
  • Signed informed consent obtained from parent or legal guardian for infant's participation in the study
  • Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for infant from birth through the length of the study period

Exclusion

  • Infant has been weighed by a health care professional (HCP) and is identified with inadequate weight gain or failure-to-thrive
  • Diagnosis or suspicion of cow's milk protein allergy by a healthcare professional
  • Any acute illness within the 3 days prior to Visit 1
  • Infant has had immunizations or a surgical procedure within the 3 days prior to or on Visit 1
  • Immunizations are planned for the infant during any of the 7 days after Visit 1
  • Use of oral, intramuscular or intravenous antibiotics within the 7 days prior to Visit 1
  • Infant has had bloody stools (visible to the naked eye) within the 7 days prior to Visit 1
  • Infant has been taking medication (prescribed and over-the-counter) for gastrointestinal conditions for any of the 7 days prior to Visit 1 (however, probiotics are allowed)
  • Infant has a surgical procedure planned during the study period
  • History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
  • History of underlying neurological or organic disease likely to cause fussiness, such as (but not limited to) a doctor's diagnosis of neonatal abstinence syndrome and inflammatory or orthopedic disorders
  • Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down syndrome or others)

Key Trial Info

Start Date :

February 28 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 14 2023

Estimated Enrollment :

148 Patients enrolled

Trial Details

Trial ID

NCT05245422

Start Date

February 28 2022

End Date

July 14 2023

Last Update

June 18 2025

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Birmingham Pediatric Associates

Birmingham, Alabama, United States, 35205

2

Alabama Clinical Therapeutics

Birmingham, Alabama, United States, 35235

3

DBC Research USA

Miramar, Florida, United States, 33025

4

Proactive Clinical Research

Sarasota, Florida, United States, 34243

Acceptance of a Partially Hydrolyzed Formula | DecenTrialz